McKesson said revenues for the 3 months ended December 31, 2024 increased 18% compared to the prior year period, and revenues for the 9 months increased 15%. Diluted earnings per common share attributable to McKesson Corporation were $6.95 for the 3 months (compared to $4.42 in the prior year) and $15.80 for the 9 months (compared to $16.39 in the prior year).

1. 01

   McKesson said revenues for the 3 months ended December 31, 2024 increased 18% compared to the prior year period, and revenues for the 9 months increased 15%. Diluted earnings per common share attributable to McKesson Corporation were $6.95 for the 3 months (compared to $4.42 in the prior year) and $15.80 for the 9 months (compared to $16.39 in the prior year).

2. 02

   The company completed the sale of its Canadian retail disposal group (Rexall and Well.ca) on December 30, 2024 for a cash payment of $9 million and a note of $120 million payable at the end of 6 years. It recorded fair value remeasurement charges of $666 million in total operating expenses for the 9 months.

3. 03

   McKesson approved enterprise-wide restructuring initiatives to modernize its technology service operating model in Q2, anticipating total charges of $650 million to $700 million, with the programs substantially complete in fiscal 2028. For the 3 months and 9 months, the company recorded charges of $18 million and $245 million, respectively.

4. 04

   For the 9 months, McKesson recorded a credit of $203 million in selling, distribution, general, and administrative expenses related to a fair value adjustment of its contingent consideration liability from the Rite Aid bankruptcy, compared to a provision for bad debts of $725 million for the 9 months in the prior year. The company also recorded a net charge of $108 million related to its estimated liability for opioid-related claims for the 9 months.

Key figures

Quarter ended December 31, 2024

Revenue

$95.3B

Operating income

$1.2B

Net income

$879M

EPS

$6.95

Gross profit

$3.3B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.